/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

New Season of Call of Duty: Black Ops 4 Content Starts Now with ‘Operation Spectre Rising’

Published

5 years ago

April 30, 2019

Reading Time: 5 minutes

Available First on PlayStation®4, Operation Spectre Rising Introduces
a Ton of Free, New Content and Updates Across the Game

Black Ops Pass Owners Gain Access to Three Additional Multiplayer
Maps, Including Two New Maps and One Remastered Classic Map and an
Exclusive Blackout Character

SANTA MONICA, Calif.–(BUSINESS WIRE)–The newest community event and seasonal release for Call of Duty®:
Black Ops 4 is available now on Playstation®4,
with other platforms to follow. Operation
Spectre Rising delivers assassin-themed updates across the
game, including a beloved Specialist, big changes to Blackout, new game
modes and personalization items, as well as adding three Multiplayer
maps and a special summer-themed event.

“The community has anticipated Spectre’s return for a long time,
and that’s inspired us to build Operation Spectre Rising
all around this shadowy, fan-favorite assassin
and the wetworks theme,” said Dan Bunting, Co-Studio Head, Treyarch.
“This new Operation delivers lots of new game modes and fun ways to play Black
Ops 4, including some really cool changes to the Blackout map
following Spectre’s dramatic introduction – players won’t want to
miss this event!”

Operation Spectre Rising’s free, new content includes:

The Assassin Specialist – Available in Multiplayer and
Blackout, Spectre introduces a new gameplay innovation with a
unique Shadow Blade melee weapon, and channels players’ inner assassin
to skillfully strike targeted enemies for quick and stealthy kills.
This fan-favorite Specialist also wields a smoke grenade that not only
provides instant cover to move undetected, but also reveals enemies.
New Blackout Updates – In Blackout, Spectre has ruptured
the famous Hydro Dam causing a massive flood, altering the landscape
and forcing players to adapt in order to survive a wide variety of
combat situations, while outrunning the Collapse. Additionally,
players will have the opportunity to discover updates in Alcatraz like
the addition of the Tactical Raft and more.
New Black Market Gear – The Black Market has been restocked
with a variety of new weapon camos, outfits, gestures, and accessories
themed for Operation Spectre Rising. This includes
notable weapons like the Tigershark LMG and the Nifo’Oti melee weapon,
all unlockable through the Contraband Tiers as fans play through the
game.
New Zombies Features – Operation Spectre Rising
introduces new weapons across all Zombies maps, Classic Elixir Restock
feature, and Hard Mode Gauntlet challenges throughout the season.

In addition to the free content, Black Ops Pass owners gain access to
even more in-game content, available first on PlayStation®4:

New Multiplayer Map, Masquerade – A medium-sized map set
amidst an embassy under siege. Masquerade is structured for
mid-range combat as players must weave through markets and city
alleyways to get to the fortified embassy courtyard.
New Multiplayer Map, Artifact – A larger-sized map set
in a remote landscape where treasure hunters have located and
unearthed an ancient artifact. The map is filled with a variety
of rock formations from thermal geysers to ice caverns. Combat is
fierce with engagement ranging across environmental hazards on a
vertical map.
New Multiplayer Map, WMD – Remastered from the original Call
of Duty: Black Ops, WMD is a medium-sized map set in an active
weapons manufacturing facility. Combat takes place in a combination of
interior and exterior engagements at different ranges that supports
all types of weapon types and playstyles.
New Blackout Character, Uncle Frank – Black Ops Pass
owners get instant access to Uncle Frank, also known as the
older version of Frank Woods. This iconic, fan-favorite character
originally from Call of Duty: Black Ops II makes his debut in
Blackout.

“The team has worked hard to offer a real diversity of content with Operation
Spectre Rising, while providing a thoughtful cadence that keeps
the experience fresh across the entire breadth of the game,” said Mark
Gordon, Co-Studio Head of Treyarch. “From Spectre debuting in
Multiplayer and Blackout, to design modifications that will allow us to
share content on a more regular basis, Operation Spectre Rising
really shifts this season into a higher gear.”

In addition to the content releasing now with Operation Spectre
Rising, spring turns into summer in June with the annual Call
of Duty Days of Summer community event. This limited-time event will
debut new game modes, seasonal themed customizations and accessories for
fans to acquire.

The Black Ops Pass* is included in the Digital Deluxe Edition,
the Digital Deluxe Enhanced Edition, the Pro Edition, and the Mystery
Box Edition of Call of Duty: Black Ops 4, and
can also be purchased standalone digitally or at participating retailers.

Call of Duty: Black Ops 4 is published by Activision and
developed by Treyarch with additional development support from Raven
Software and PC development with Beenox. For the latest intel check out: www.callofduty.com, www.youtube.com/callofduty and
follow @CallofDuty
and @Treyarch
on Twitter, Instagram
and Facebook.
The game is rated M for Mature (Blood and Gore, Drug Reference, Intense
Violence, Strong Language).

*Black Ops Pass (BOP) content is not final, is subject to change, and
may not include all downloadable content available for the game. BOP
content may not be available in all countries, and pricing and release
dates may vary by platform. BOP content should be downloaded from the
in-game store only; do not purchase separately, or you will be charged
again. BOP content may be sold separately.

About Treyarch

Treyarch is an award-winning video game studio, driven by the desire to
create epic gameplay experiences that are enjoyed by as many video game
fans as possible. It is an approach that has helped to make the studio
behind the Call of Duty®: Black Ops series of games an
industry-leading developer. Call of Duty: Black Ops set an
entertainment launch opening record upon its release in 2010 and
continues to be one of the best-selling games of all time, according to
NPD and GfK Chart-Track; Call of Duty®: Black Ops II set
world-wide launch day records; and Call of Duty®: Black Ops III held
the biggest entertainment opening weekend of 2015, and was the #1
console game globally for the calendar year. Call of Duty: Black Ops 4
is the studio’s most recent release. Additionally,
Treyarch is the birthplace of Call of Duty’s Zombies. Treyarch is wholly
owned by Activision.

About Activision

Headquartered in Santa Monica, California, Activision is a leading
global producer and publisher of interactive entertainment. Activision
maintains operations throughout the world and is a division
of Activision Blizzard (NASDAQ: ATVI), an S&P 500 company. More
information about Activision and its products can be found on the
company’s website, www.activision.com or
by following @Activision.

Cautionary Note Regarding Forward-looking Statements: Information in
this press release that involves Activision Publishing’s expectations,
plans, intentions or strategies regarding the future, including
statements about the expected availability, features, functionality,
events and content for Operation Spectre Rising and the
Black Ops Pass, are forward-looking statements that are not facts and
involve a number of risks and uncertainties. Factors that could
cause Activision Publishing’s actual future results to differ materially
from those expressed in the forward-looking statements set forth in this
release include unanticipated product delays and other factors
identified in the risk factors sections of Activision Blizzard’s most
recent annual report on Form 10K and any subsequent quarterly reports on
Form 10-Q. The forward-looking statements in this release are based upon
information available to Activision Publishing and Activision
Blizzard as of the date of this release, and neither Activision
Publishing nor Activision Blizzard assumes any obligation to update any
such forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These statements
are not guarantees of the future performance of Activision
Publishing or Activision Blizzard and are subject to risks,
uncertainties and other factors, some of which are beyond its control
and may cause actual results to differ materially from current
expectations.

ACTIVISION, CALL OF DUTY, and CALL OF DUTY BLACK OPS are trademarks
of Activision Publishing, Inc. All other trademarks and trade names are
the properties of their respective owners.

Contacts

Kelvin Liu
Senior Manager, Public Relations
Activision
310.255.2213
[email protected]

Cannabis

Cannabis Testing Market Worth $4.0 billion | MarketsandMarkets™

Published

1 day ago

May 23, 2024

CISION (PR Newswire)

CHICAGO, May 23, 2024 /PRNewswire/ — Cannabis Testing Market in terms of revenue was estimated to be worth $1.8 billion in 2024 and is poised to reach $4.0 billion by 2029, growing at a CAGR of 17.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The important factors impacting market growth are legalization trends and rising medical applications for cannabis. Rising approvals for medical and recreational cannabis drive the regulations requiring product safety testing which in turn fuel the need for cannabis testing services. Additionally, the rise in the number of cannabis testing labs due to legalization is propelling the demand for analytical instruments is likely to uplift market growth in coming years.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46932450

Browse in-depth TOC on “Cannabis Testing Market”
439 – Tables
52 – Figures
378 – Pages

Cannabis Testing Market Scope:

Report Coverage	Details
Market Revenue in 2024	$1.8 billion
Estimated Value by 2029	$4.0 billion
Growth Rate	Poised to grow at a CAGR of 17.2%
Market Size Available for	2022–2029
Forecast Period	2024–2029
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Product & Software, By Service & By End User
Geographies Covered	North America, Europe, the Asia Pacific, Latin America and the Middle East & Africa
Report Highlights	Updated financial information / product portfolio of players
Key Market Opportunities	Untapped markets in emerging economies
Key Market Drivers	Increasing legalization of medical and recreational cannabis

Products segment held the highest estimated share of the cannabis testing market.

Based on product & software, the cannabis testing market is segmented into products (analytical instruments {chromatography instruments [liquid chromatography, gas chromatography & other chromatography instruments], spectroscopy instruments [mass spectrometry instruments & atomic spectroscopy instruments] & other analytical instruments} and consumables {chromatography columns, standards and CRMS, sample preparation products and other consumables) and software. The product segment accounted for the largest share of the cannabis testing market in 2023. Market growth is driven by technological advancements providing sophisticated tools for precise analysis, ensuring compliance and quality control, and the expanding legalization of cannabis products. Additionally, increasing requirements for potency labeling and pesticide screening fuel the demand for specialized consumables, further propelling growth in the cannabis testing market. For example, Thermo Fisher Scientific Inc. launched the Thermo Scientific SureSTART consumables portfolio consisting of vials, well plates, caps, inserts, kits, and mats to improve analytical performance and sample security for chromatography and mass spectrometry users in routine and research labs in clinical, food, pharma, biopharma, environmental, and academic sectors.

High growth of services segment attributed to potency testing services.

Based on service, the cannabis testing market is broadly segmented into terpene profiling, microbial analysis, residual solvent analysis, potency testing, heavy metal testing, pesticide screening, and other services. In 2023, potency testing accounted for the largest share of the cannabis testing services market. The high growth of this segment is due to stringent regulatory requirements ensuring accurate THC and CBD levels. This is crucial for product labeling, consumer safety, and compliance, driving demand from producers and dispensaries seeking to meet legal standards and provide reliable, high-quality products.

Services take away the largest estimated share of the end-user segment.

Based on end users, the cannabis testing market is classified into segmented into product & software end users (cannabis testing laboratories {small-scale laboratories, medium-scale laboratories, large-scale laboratories} and research institutes) and service end users (cannabis drug manufacturers & dispensaries, cannabis cultivators/growers). In 2023, the service end users’ segment was predicted to account for the highest share of the global cannabis testing market. The large share of this end user segment is due to the rising consumer awareness of quality and safety, rising legalization of cannabis, stringent regulatory standards, and technological advancements in cannabis testing.

During the forecast period, North America displayed lucrative market growth.

North America accounted for the largest share of 65.5% of the cannabis testing market in 2023. The North American market is projected to reach a value of USD 2.6 billion by 2029 from an estimated value of USD 1.2 million in 2024, at a CAGR of 17.3% during the forecast period. The region leads the cannabis testing market due to stringent regulatory standards, robust infrastructure, and widespread legalization of cannabis for medical and recreational purposes. Additionally, North America’s advanced R&D capabilities and evolving consumer demand for quality assurance drive its prominence in this growing sector.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=46932450

Cannabis Testing Market Dynamics:

Drivers:

Increasing legalization of medical and recreational cannabis
Increasing use of cannabis for medicinal applications
Technological advancements in testing technologies

Restraints:

Lack of standardization
Investment risks due to regularization

Opportunities:

Untapped markets in emerging economies
Research collaborations

Challenge:

High setup costs

Key Market Players of Cannabis Testing Industry:

The global cannabis testing market comprises many key market players competing for markets shares like Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Waters Corporation (US), Restek Corporation (US), SGS SA (Switzerland), Merck KGaA (Germany), PerkinElmer, Inc. (US), Hamilton Company (US), Sigma Analytical Services (Canada), SC Labs (US), PharmLabs LLC (US), MCS, Inc. (US), ProVerde Laboratories (US), and Eurofins Scientific (Luxembourg).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70%, and Demand Side – 30%
By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

Recent Developments:

In September 2023, Shimadzu Corporation launched the Brevis GC-2050 gas chromatograph used in various applications including cannabis testing.
In April 2023, SC Labs, one of the leading cannabis testing companies, acquired C4 Laboratories, one of the first Arizona cannabis labs, thus allowing it to be licensed and accredited in five states: California, Colorado, Michigan, Oregon, and Arizona.
In June 2022, Shimadzu Corporation launched the AA-7800 series atomic absorption spectrophotometers. The AA-7800 series is used for quality control in the raw material, food, and for inspecting water quality and hazardous substances in soil thus presenting an advantage in heavy metal testing of cannabis.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=46932450

Cannabis Testing Market – Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cannabis testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (increasing legalization of medical and recreational cannabis, increasing use of cannabis for medicinal applications and technological advancements in testing technologies), restraints (lack of standardization and investment risks due to regularization), opportunities (untapped markets in emerging economies and research collaborations) and challenges (high setup costs) are influencing the growth of cannabis testing market.
Product Development/Innovation: Detailed insights on newly launched products of the cannabis testing market.
Market Development: Comprehensive information about lucrative markets – the report analyses the cannabis testing market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cannabis testing market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Waters Corporation (US), Restek Corporation (US), SGS SA (Switzerland), Merck KGaA (Germany), PerkinElmer, Inc. (US), Hamilton Company (US), Sigma Analytical Services (Canada), SC Labs (US), PharmLabs LLC (US), MCS, Inc. (US), ProVerde Laboratories (US), and Eurofins Scientific (Luxembourg) among others in the cannabis testing market.

Related Reports:

Drug Screening Market – Global Forecasts to 2029

Laboratory Proficiency Testing Market – Global Forecasts to 2028

Life Science Instrumentation Market – Global Forecasts to 2028

Digital PCR Market – Global Forecasts to 2028

Flow Cytometry Market – Global Forecasts to 2028

Get access to the latest updates on Cannabis Testing Companies and Cannabis Testing Industry Growth

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cannabis-testing-market-worth-4-0-billion–marketsandmarkets-302154066.html

Cannabis

Solei Brand Introduces New Cannabis-Infused ‘Warming Deep Tissue Stick’

Published

2 days ago

May 23, 2024

GlobeNewswire

Granted

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain

Published

3 days ago

May 21, 2024

CISION (PR Newswire)

The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan’s LPT-CBD release technology, marking a key step in the advancement of non-opioid pain management

HERZLIYA, Israel and CALGARY, AB, May 21, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce significant advancements in the regulatory process for its Liposome-Cannabidiol (LPT-CBD) technology, which provides an innovative solution in non-opioid pain management. The U.S. Food and Drug Administration (“FDA”) has granted Innocan an Investigational New Drug (“IND”) number and approved an initial meeting with the Company to discuss the strategic path forward.

The meeting with the FDA has been set for July 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain.

“We are very pleased with this crucial step towards launching our IND program for LPT-CBD in the United States,” commented Iris Bincovich CEO of Innocan Pharma. “This upcoming FDA consultation is pivotal, poised to set the stage for our clinical trials and drive forward our mission to revolutionize pain management. We look forward to the FDA reviewing our development program and providing us with guidance on our advancement to human clinical trials.”

Continued Iris Bincovich, CEO, “I thank Prof. Chezy Barenholz and Dr. Ahuva Cern of the Hebrew University of Jerusalem, renowned experts in liposome research, for their continued efforts providing strong supportive data on LPT-CBD, enabling our upcoming engagement with FDA.”

LPT therapy, which requires only one single monthly subcutaneous injection, offers a groundbreaking alternative to opioid-based approaches. Addressing the critical opioid crisis, where, according to the U.S. Centers for Disease Control and Prevention, over three-quarters of drug overdose deaths in the U.S. involve opioids, Innocan’s LPT-CBD presents a compelling, life-saving alternative. In multiple pre-clinical trials, Innocan’s therapy has shown consistent efficacy of its LPT-CBD injectable treatment, through prolonged and controlled release of CBD in animals with chronic pain conditions.

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fda-has-granted-innocan-pharma-a-meeting-date-for-lpt-cbd-for-chronic-pain-302151667.html

Cannabis2 weeks ago

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Cannabis2 weeks ago

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa